Literature DB >> 35981542

Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression.

Ioannis Sanidas1, Hanjun Lee2, Purva H Rumde1, Gaylor Boulay3, Robert Morris1, Gabriel Golczer1, Marcelo Stanzione1, Soroush Hajizadeh1, Jun Zhong1, Meagan B Ryan1, Ryan B Corcoran1, Benjamin J Drapkin4, Miguel N Rivera3, Nicholas J Dyson5, Michael S Lawrence6.   

Abstract

The interaction of RB with chromatin is key to understanding its molecular functions. Here, for first time, we identify the full spectrum of chromatin-bound RB. Rather than exclusively binding promoters, as is often described, RB targets three fundamentally different types of loci (promoters, enhancers, and insulators), which are largely distinguishable by the mutually exclusive presence of E2F1, c-Jun, and CTCF. While E2F/DP facilitates RB association with promoters, AP-1 recruits RB to enhancers. Although phosphorylation in CDK sites is often portrayed as releasing RB from chromatin, we show that the cell cycle redistributes RB so that it enriches at promoters in G1 and at non-promoter sites in cycling cells. RB-bound promoters include the classic E2F-targets and are similar between lineages, but RB-bound enhancers associate with different categories of genes and vary between cell types. Thus, RB has a well-preserved role controlling E2F in G1, and it targets cell-type-specific enhancers and CTCF sites when cells enter S-phase.
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AP-1; CTCF; E2F; PanChIP; RB phosphorylation; RB-bound enhancers; RB-bound promoters; cell-cycle regulation; regulation of RB activity; retinoblastoma protein

Mesh:

Substances:

Year:  2022        PMID: 35981542      PMCID: PMC9481721          DOI: 10.1016/j.molcel.2022.07.014

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   19.328


  79 in total

1.  The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation.

Authors:  D M Thomas; S A Carty; D M Piscopo; J S Lee; W F Wang; W C Forrester; P W Hinds
Journal:  Mol Cell       Date:  2001-08       Impact factor: 17.970

2.  RB and hbrm cooperate to repress the activation functions of E2F1.

Authors:  D Trouche; C Le Chalony; C Muchardt; M Yaniv; T Kouzarides
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

3.  Rb binds c-Jun and activates transcription.

Authors:  M A Nead; L A Baglia; M J Antinore; J W Ludlow; D J McCance
Journal:  EMBO J       Date:  1998-04-15       Impact factor: 11.598

Review 4.  Integrating Old and New Paradigms of G1/S Control.

Authors:  Seth M Rubin; Julien Sage; Jan M Skotheim
Journal:  Mol Cell       Date:  2020-09-17       Impact factor: 17.970

5.  The Rb/E2F pathway modulates neurogenesis through direct regulation of the Dlx1/Dlx2 bigene cluster.

Authors:  Noël Ghanem; Matthew G Andrusiak; Devon Svoboda; Sawsan M Al Lafi; Lisa M Julian; Kelly A McClellan; Yves De Repentigny; Rashmi Kothary; Marc Ekker; Alexandre Blais; David S Park; Ruth S Slack
Journal:  J Neurosci       Date:  2012-06-13       Impact factor: 6.167

6.  Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth.

Authors:  Francesca Zanconato; Mattia Forcato; Giusy Battilana; Luca Azzolin; Erika Quaranta; Beatrice Bodega; Antonio Rosato; Silvio Bicciato; Michelangelo Cordenonsi; Stefano Piccolo
Journal:  Nat Cell Biol       Date:  2015-08-10       Impact factor: 28.824

7.  Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.

Authors:  Caryn S Ross-Innes; Rory Stark; Andrew E Teschendorff; Kelly A Holmes; H Raza Ali; Mark J Dunning; Gordon D Brown; Ondrej Gojis; Ian O Ellis; Andrew R Green; Simak Ali; Suet-Feung Chin; Carlo Palmieri; Carlos Caldas; Jason S Carroll
Journal:  Nature       Date:  2012-01-04       Impact factor: 49.962

8.  The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Authors:  Jordi Barretina; Giordano Caponigro; Nicolas Stransky; Kavitha Venkatesan; Adam A Margolin; Sungjoon Kim; Christopher J Wilson; Joseph Lehár; Gregory V Kryukov; Dmitriy Sonkin; Anupama Reddy; Manway Liu; Lauren Murray; Michael F Berger; John E Monahan; Paula Morais; Jodi Meltzer; Adam Korejwa; Judit Jané-Valbuena; Felipa A Mapa; Joseph Thibault; Eva Bric-Furlong; Pichai Raman; Aaron Shipway; Ingo H Engels; Jill Cheng; Guoying K Yu; Jianjun Yu; Peter Aspesi; Melanie de Silva; Kalpana Jagtap; Michael D Jones; Li Wang; Charles Hatton; Emanuele Palescandolo; Supriya Gupta; Scott Mahan; Carrie Sougnez; Robert C Onofrio; Ted Liefeld; Laura MacConaill; Wendy Winckler; Michael Reich; Nanxin Li; Jill P Mesirov; Stacey B Gabriel; Gad Getz; Kristin Ardlie; Vivien Chan; Vic E Myer; Barbara L Weber; Jeff Porter; Markus Warmuth; Peter Finan; Jennifer L Harris; Matthew Meyerson; Todd R Golub; Michael P Morrissey; William R Sellers; Robert Schlegel; Levi A Garraway
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

Review 9.  The broken cycle: E2F dysfunction in cancer.

Authors:  Lindsey N Kent; Gustavo Leone
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

10.  RB localizes to DNA double-strand breaks and promotes DNA end resection and homologous recombination through the recruitment of BRG1.

Authors:  Renier Vélez-Cruz; Swarnalatha Manickavinayaham; Anup K Biswas; Regina Weaks Clary; Tolkappiyan Premkumar; Francesca Cole; David G Johnson
Journal:  Genes Dev       Date:  2016-11-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.